bioAffinity Technologies (BIAF) Operating Expenses (2021 - 2026)

bioAffinity Technologies has disclosed Operating Expenses across 6 years of filings, most recently posting $928636.0 for Q1 2026.

• In Q1 2026, Operating Expenses fell 32.11% year-over-year to $928636.0; the TTM figure through Mar 2026 stood at $13.2 million (down 14.02% YoY), while the FY2025 annual figure was $16.7 million, down 8.63% from the prior year.
• Operating Expenses fell to $928636.0 in Q1 2026, from $4.7 million in the prior quarter.
• Over the last five years, Operating Expenses for BIAF reached as high as $5.2 million in Q4 2024 and fell as low as $685279.0 in Q2 2022.
• The 5-year median for Operating Expenses is $2.6 million (2023), against an average of $2.8 million.
• Annual changes were most pronounced in 2023 — Operating Expenses jumped 180.12% — and 2025, when it tumbled 68.57%.
• A 5-year view of Operating Expenses shows it stood at $1.6 million in 2022, then jumped by 180.12% to $4.6 million in 2023, then rose by 13.13% to $5.2 million in 2024, then decreased by 8.23% to $4.7 million in 2025, then sank by 80.37% to $928636.0 in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $928636.0, $4.7 million, and $3.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.